Cover Image
市場調查報告書

Bicalutamide的中國市場

Investigation Report on China Bicalutamide Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 337522
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Bicalutamide的中國市場 Investigation Report on China Bicalutamide Market, 2010-2019
出版日期: 2015年08月18日 內容資訊: 英文 30 Pages
簡介

Bicalutamide是由AstraZeneca所開發的,非類固醇系、抗雄性素口服藥,在進行性前列腺癌症的治療時,與外科手術並用。中國國內的銷售額,從2005年的1400萬人民幣,2014年達到2億3200萬人民幣以上,年複合成長率(CAGR) 以37.6%速度擴大。

本報告提供中國的Bicalutamide的市場相關分析、Bicalutamide的特徵和認證情形、市場整體規模、各企業、各劑型的市場佔有率、價格趨勢、主要製造商簡介、今後的市場成長預測等調查評估。

第1章 Bicalutamide的相關概念

  • 適應症
  • 全球市場的銷售情形

第2章 中國的Bicalutamide市場簡介

  • 中國國內的Bicalutamide的專利申請、核準情況
  • 主要製造商
  • 市場規模

第3章 中國國內的Bicalutamide銷售額分析 (過去5年份)

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售量

第4章 Bicalutamide的主要廠商的市場佔有率 (過去5年份)

  • 市場佔有率 (以金額為準)
  • 市場佔有率 (以數量為準)

第5章 中國國內的Bicalutamide的劑型 (過去5年份)

  • 各劑型的市場佔有率 (以金額為準)
  • 各劑型的市場佔有率 (以數量為準)

第6章 中國的醫院的Bicalutamide的參照價格

  • AstraZeneca (德國)
  • Zhendong Group
  • Shanghai Zhaohui Pharmaceutical Co., Ltd.
  • Zhejiang Hisun Pharmaceutical Co.,Ltd.
  • Shanghai Fudan Forward Pharmaceutical Co., Ltd.

第7章 中國國內的Bicalutamide的主要製造商 (過去5年份)

  • AstraZeneca (德國)
  • Zhendong Group
  • Shanghai Zhaohui Pharmaceutical Co., Ltd.
  • Zhejiang Hisun Pharmaceutical Co.,Ltd.
  • Shanghai Fudan Forward Pharmaceutical Co., Ltd.
  • Forward

第8章 中國國內的Bicalutamide市場未來展望 (今後5年份)

  • 市場規模的預測
  • 競爭環境的預測

圖表一覽

目錄
Product Code: 1508305

Originally developed by AstraZeneca and produced by some makers of generic drugs, bicalutamide is an oral non-steroidal antiandrogen. And it was approved in 1995 as a combination treatment with surgical castration for advanced prostate cancer. For patients unwilling to receive surgical castration, it is a good news that bicalutamide has since also been widely used as a monotherapy for the treatment of earlier stages of the disease.

In the US, prostate cancer is the second leading cause of male death with one in seven men suffering from it. Generally, elder people fall victim to prostate cancer which is caused by an excess of male hormones including testosterone i.e. androgen. Therefore, the regular treatment of prostate cancer is reducing androgen level in patients by surgical castration or ADT. In China, prostate cancer reports an incidence which ranks sixth in male malignant tumor and gradually increases with age before reaching a peak among people aged 70-80. And patients with a family history of the disease report earlier onset, among which 43% are 55 or younger than 55.

According to CRI's market survey, the sales value of bicalutamide in sample hospitals rose from less than CNY 14 million in 2005 to over CNY 232 million in 2014 with CAGR during this period reaching 37.6%. And AstraZeneca (Germany), Zhendong Group, Shanghai Fudan Forward Pharmaceutical Co., Ltd. , Hisun and Shanghai Zhaohui Pharmaceutical Co., Ltd. occupy the market, among which AstraZeneca (Germany) had the largest market share of over 80% for sales value in 2014.

By the end of 2014, the number of people aged above 60 will reach 212 million and account for 15.5% of the total population in China. With ageing population, the incidence of is expected to increase, which stimulates the market demand for such prostate cancer drugs as bicalutamide.

Readers can get at least the following information through this report:

  • market size of bicalutamide in China
  • competitive landscape of bicalutamide market in China
  • price of bicalutamide made by different enterprises in China
  • market outlook of bicalutamide in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-tumor agents
  • investors/research institutions interested in Chinese medicine market
  • -any interest in Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Bicalutamide

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Bicalutamide in China

  • 2.1. Patent and Approval Information of Bicalutamide in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Bicalutamide Sales in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Bicalutamide Manufacturers in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Bicalutamide in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Bicalutamide in Chinese Hospitals in 2014

  • 6.1. AstraZeneca (Germany)
  • 6.2. Zhendong Group
  • 6.3. Shanghai Zhaohui Pharmaceutical Co., Ltd.
  • 6.4. Zhejiang Hisun Pharmaceutical Co.,Ltd.
  • 6.5. Shanghai Fudan Forward Pharmaceutical Co., Ltd.

7. Major Manufacturers of Bicalutamide in Chinese Market, 2010-2014

  • 7.1. AstraZeneca (Germany)
  • 7.2. Zhendong Group
  • 7.3. Shanghai Zhaohui Pharmaceutical Co., Ltd.
  • 7.4. Zhejiang Hisun Pharmaceutical Co.,Ltd.
  • 7.5. Shanghai Fudan Forward Pharmaceutical Co., Ltd.
  • 7.5. Forward

8. Market Outlook of Bicalutamide in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Approval Information of Bicalutamide in China
  • Chart Bicalutamide Sales in China
  • Chart Sales Value of Bicalutamide in China, 2010-2014
  • Chart Sales Value of Bicalutamide in Some Regions in China, 2010-2014
  • Chart Sales Volume of Bicalutamide in China, 2010-2014
  • Chart Sales Volume of Bicalutamide in Some Regions in China, 2010-2014
  • Chart Market Share of TOP5 Bicalutamide Manufacturers for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Bicalutamide Made by AstraZeneca (Germany) in China, 2010-2014
  • Chart Sales Value and Market Share of Bicalutamide Made by Zhendong Group in China, 2010-2014
  • Chart Sales Value and Market Share of Bicalutamide Made by Shanghai Zhaohui Pharmaceutical Co., Ltd. in China, 2010-2014
  • Chart Sales Value and Market Share of Bicalutamide Made by Hisun in China, 2010-2014
  • Chart Sales Value and Market Share of Bicalutamide Made by Forward in China, 2010-2014
  • Chart Sales Value and Market Share of Bicalutamide Tablet in China, 2010-2014
  • Chart Price of Bicalutamide Made by AstraZeneca (Germany) in Some Chinese Cities in 2014
  • Chart Price of Bicalutamide Made by Zhendong Group in Some Chinese Cities in 2014
  • Chart Price of Bicalutamide Made by Shanghai Zhaohui Pharmaceutical Co., Ltd. in Some Chinese Cities in 2014
  • Chart Price of Bicalutamide Made by Hisun in Some Chinese Cities in 2014
  • Chart Price of Bicalutamide Made by Forward in Some Chinese Cities in 2014
Back to Top